Citius Pharmaceuticals(NASDAQ) CTXR

Current Price$0.53

Market Cap$13.19M

Since IPO (2014)-100%

5 Year-99%

1 Year-69%

1 Month-12%

Citius Pharmaceuticals last closing stock price
Metric	Price	Date
Last close	USD 0.48	2026-07-20

Citius Pharmaceuticals stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-11%	USD 0.54	2026-07-13
1 month	-12.04%	USD 0.55	2026-06-18
3 month	-43.12%	USD 0.84	2026-04-21
Year to date	-38.15%	USD 0.78	2025-12-31
1 year	-68.59%	USD 1.53	2025-07-18
3 year	-98.36%	USD 29.25	2023-07-21
5 year	-99.08%	USD 52.00	2021-07-21
Since inception	-99.87%	USD 374.98	2014-10-02

Citius Pharmaceuticals Financials at a Glance

Market Cap

$13.19M

Revenue (TTM)

$5.61M

Net Income (TTM)

-$46.20M

EPS (TTM)

-$2.57

P/E Ratio

-0.19

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Price

$0.53

Volume

696,261.006

Open

$0.49

Price

$0.53

Volume

696,261.006

Open

$0.49

Previous Close

$0.48

Daily Range

$0.49 - $0.55

52-Week Range

$0.47 - $2.19

Estimated Earnings Date

Aug 11, 2026

Dividend

$0.00

Beta (Volatility)

1.19 (Average)

Price

$0.53

Volume

696,261.006

Open

$0.49

Previous Close

$0.48

Daily Range

$0.49 - $0.55

52-Week Range

$0.47 - $2.19

Estimated Earnings Date

Aug 11, 2026

CTXR News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Citius Pharmaceuticals

Citius develops medicines for serious infections and rare cancers. Its products help patients with blood infections and skin lymphomas. The company also works on treatments for hemorrhoids and severe lung conditions.

What’s in the Medicine Cabinet?

LYMPHIR: FDA-approved drug for rare skin lymphoma, targeting patients with persistent or recurring disease. (0% of revenue as of September 2024)
Mino-Lok: Antibiotic solution to treat bloodstream infections from catheters, aiming to save the device. (0% of revenue as of September 2024)
Halo-Lido: Topical cream for hemorrhoid relief, combining anti-inflammatory and pain-numbing agents. (0% of revenue as of September 2024)
NoveCite: Stem cell therapy in early development for acute respiratory distress syndrome, a severe lung condition. (0% of revenue as of September 2024)
Mino-Wrap: Gel wrap for infection prevention after breast reconstruction; development stopped in December 2023. (0% of revenue as of September 2024)

Growth Spurts and Growing Pains

Acquired Leonard-Meron Biosciences in 2016, adding Mino-Lok to its pipeline.
Formed Citius Oncology in 2023 to commercialize LYMPHIR; completed reverse merger in August 2024.
Secured FDA approval for LYMPHIR in August 2024, with commercial launch planned for 2025.
Discontinued Mino-Wrap development in December 2023 to focus resources on core products.
Outsources all manufacturing to third-party partners, avoiding capital-intensive facilities.

Why Citius Catches the Eye

Citius focuses on late-stage drugs and new uses for existing medicines, reducing development risk. It targets markets with few treatment options, using regulatory incentives for exclusivity. The company relies on partnerships for manufacturing and sales, keeping operations lean.

Five Things You Need to Know

Revenue was $0 in Q3 2025, unchanged from Q3 2024 and Q3 2023.
Net loss was $41,367 in Q3 2025, improving 21.7% from Q3 2024.
Cash used in operations was $5 million in Q3 2025, improving 35.4% year-over-year.
Cash and equivalents fell to $3.3 million as of September 30, 2024.
Company had 23 full-time employees and a market cap of $11.62 million in September 2024.

Bottom Line

Citius has shifted from research to launching its first commercial product. The company remains focused on niche treatments and faces ongoing financial challenges.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

CEO

Leonard L. Mazur, MBA

Website

www.citiuspharma.com

Headquarters

Cranford, NJ 07016, US

CTXR Financials

Key Financial Metrics (TTM)

Gross Margin

37.36%

Operating Margin

-1041.44%

Net Income Margin

-823.34%

Return on Equity

-67.42%

Return on Capital

-55.54%

Return on Assets

-34.86%

Earnings Yield

-5.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$13.19M

Shares Outstanding

27.45M

Volume

696.26K

Avg. Volume

612.78K

Financials (TTM)

Gross Profit

$2.10M

Operating Income

-$58.44M

EBITDA

-$55.93M

Operating Cash Flow

-$31.60M

Capital Expenditure

$4.00

Free Cash Flow

-$31.60M

Cash & ST Invst.

$4.59M

Total Debt

$808.16K

Citius Pharmaceuticals Performance Analysis

Citius Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-09-30	USD 0	N/A
2023	2023-09-30	USD 0	N/A
2024	2024-09-30	USD 0	N/A
2025	2025-09-30	USD 0	N/A

Citius Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-06-30	N/A
Q4	2025-09-30	N/A
Q1	2025-12-31	N/A
Q2	2026-03-31	-57.7%

Citius Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-09-30	USD -5.76	2.1%
2023	2023-09-30	USD -5.57	-3.3%
2024	2024-09-30	USD -5.97	7.3%
2025	2025-09-30	USD -3.38	-43.4%

Citius Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-06-30	37.0%
Q4	2025-09-30	45.0%
Q1	2025-12-31	13.6%
Q2	2026-03-31	-150.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$1.67M

N/A

Gross Profit

-$381.89K

N/A

Gross Margin

-22.90%

N/A

Market Cap

$13.19M

N/A

Market Cap/Employee

$573.64K

N/A

Employees

N/A

Net Income

-$21.23M

-94.5%

EBITDA

-$30.43M

-171.9%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$4.59M

+17280.4%

Total Debt

$808.16K

-13.3%

Accounts Receivable

$1.08M

N/A

Inventory

$22.66M

+47.7%

Long Term Debt

$636.67K

-19.1%

Short Term Debt

$171.50K

+18.2%

Return on Assets

-34.86%

N/A

Return on Invested Capital

-75.38%

N/A

Free Cash Flow

-$1.30M

+71.4%

Operating Cash Flow

-$1.30M

+71.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

LNAILunai Bioworks Inc.

LNAILunai Bioworks Inc.$2.91+10.23%

DAREDare Bioscience, Inc.

DAREDare Bioscience, Inc.$1.32-1.49%

MBRXMoleculin Biotech, Inc.

MBRXMoleculin Biotech, Inc.$2.17+1.17%

ICUSeaStar Medical Holding Corporation

ICUSeaStar Medical Holding Corporation$3.90+1.30%

CRISCuris, Inc.

CRISCuris, Inc.$5.00+10.62%

APLMApollomics, Inc.

APLMApollomics, Inc.$18.57-1.54%

FBLGFibroBiologics, Inc. Common Stock

FBLGFibroBiologics, Inc. Common Stock$0.78+0.01%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

VIVKVivakor

VIVKVivakor$5.49+2.17%

UTZUtz Brands

UTZUtz Brands$14.12+0.89%

AALAmerican Airlines Group

AALAmerican Airlines Group$15.28+0.01%

SOFISoFi Technologies

SOFISoFi Technologies$17.44+0.02%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$11.37+0.06%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$34.83+0.23%

CONLGraniteShares ETF Trust - GraniteShares 2x Long Coin Daily ETF

CONLGraniteShares ETF Trust - GraniteShares 2x Long Coin Daily ETF$6.25+0.25%

Questions About CTXR

What is the current price of Citius Pharmaceuticals?

Citius Pharmaceuticals is trading at $0.54 per share.

What is the 52-week range for Citius Pharmaceuticals?

Over the past 52 weeks, Citius Pharmaceuticals has traded between $0.47 and $2.19.

How much debt does Citius Pharmaceuticals have?

As of the most recent reporting period, Citius Pharmaceuticals reported total debt of $808.16K.

How much cash does Citius Pharmaceuticals have on hand?

Citius Pharmaceuticals reported $4.59M in cash and cash equivalents in its most recent financial results.

What is Citius Pharmaceuticals’s dividend yield?

Citius Pharmaceuticals does not currently have a dividend yield.

Citius Pharmaceuticals(NASDAQ) CTXR

Citius Pharmaceuticals Financials at a Glance

CTXR News

Citius Posts Wider Loss in Fiscal Q3

Could Citius Pharmaceuticals Be a Millionaire-Maker Stock?

Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today

Is It Too Late to Buy Citius Pharmaceuticals Stock?

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Citius Pharmaceuticals

What’s in the Medicine Cabinet?

Growth Spurts and Growing Pains

Why Citius Catches the Eye

Five Things You Need to Know

Bottom Line

CTXR Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Citius Pharmaceuticals Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CTXR

What is the current price of Citius Pharmaceuticals?

What is the 52-week range for Citius Pharmaceuticals?

How much debt does Citius Pharmaceuticals have?

How much cash does Citius Pharmaceuticals have on hand?

What is Citius Pharmaceuticals’s dividend yield?

Premium Investing Services